<DOC>
	<DOCNO>NCT00341003</DOCNO>
	<brief_summary>This study , conduct National Center Malaria Control Cambodia 's Ministry Health , Guangzhou University Traditional Chinese Medicine People 's Republic China , U.S. National Institutes Health , explore people mild malaria progress severe form disease malaria parasites resistant treatment . Malaria cause parasite transmitted human mosquito bite . It cause fever , ache , weakness . Left untreated , cause severe illness even death . Malaria cure treated effective medicine , malaria parasite resistant medicine . Children adult malaria symptom parasites blood recruit study Pursat Regional Health Center Cambodia Thai-Cambodian border area within Pursat Province . Participants hospitalize 4 6 day Pursat Regional Health Center . A small blood sample collect genetic study look substance blood , certain protein , may help protect severe malaria . Patients treat two dos Artequick ( Registered Trademark ) ( artemisinin-piperaquine ) , first dose upon arrival hospital second next day . ( Participants pregnant treat either quinine artesunate-mefloquine instead Artequick . ) Patients undergo fingersticks several time hospital stay collect small drop blood monitor parasite count . They discharge hospital symptom resolve parasite longer detect blood . After discharge , patient return clinic week 3 week blood test monitor parasite , parasite may slightly resistant medication . Patients symptoms parasite reappear undergo treatment artesunate mefloquine .</brief_summary>
	<brief_title>Severe Malaria Anti-malarial Drug Resistance Cambodia</brief_title>
	<detailed_description>Hemoglobin E ( HbE ) distinguish normal HbA single amino acid mutation ( beta26 : Glu Lys ) . High allele frequency area Cambodia believe naturally select life-threatening manifestation malaria . Few epidemiological study support hypothesis , however , vitro study clearly define mechanism protection . The prevalence drug-resistant malaria alarmingly high along Thai-Cambodian border , chloroquine , quinine , mefloquine longer effect acceptable cure rate . Recently , prolong parasite clearance time artemisinin treatment document Battambang Pailin provinces Cambodia . Combinations artemisinins drug ( e.g. , mefioquine , piperaquine ) use standard first-line treatment P. falciparum malaria Southeast Asia . Further decrease effectiveness drug would constitute disaster , make case malaria essentially untreatable . The molecular basis parasite resistance antimalarial firmly establish . The main aim study ( 1 ) determine whether HbE protect severe P. falciparum malaria , ( 2 ) identify genetic determinant associate parasite resistance antimalarial drug , ( 3 ) determine whether HbE erythrocyte polymorphisms influence parasite clearance time artemisinin treatment . To meet aim , conduct unmatched case-control study compare prevalence HbE patient severe uncomplicated P. falciparum malaria . Cambodians complain fever and/or symptoms malaria recruit Pursat Regional Health Center surround district within Pursat Province . Patients uncomplicated malaria treat weight-based dos artesunate give orally day 3 day , follow weight-based dos mefloquine give orally day 2 day . Patients severe malaria treat artemisinin compound give parenterally 5 consecutive day , follow artesunate plus mefioquine treatment , . We also collect parasitized blood sample malaria patient prior antimalarial drug administration . These parasite test short-term vitro culture experiment determine susceptibility antimalarial drug . Genome-wide type drug-sensitive drug-resistant P. falciparum isolates ( use microsatellite single nucleotide polymorphism marker ) genetic association study use identify gene determine parasite response various antimalarial drug .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>INCLUSION CRITERIA : Uncompleted malaria : Age great 10 year axillary , temperature great 37.5 degree Celsius history fever , sign symptom malaria ( e.g . headache , body ache , malaise ) , asexual parasitemia great equal 10000/ul , NO criterion severe malaria NO etiology febrile illness ( e.g. , respiratory tract infection ) clinical examination , NO history antimalarial drug use present symptom . Severe malaria : Age great equal 10 year , asexual parasitemia great equal 10000/uL , NO history antimalarial drug use present symptom , one following : coma ( define Glasgow coma score less equal 9 adult , Blantyre coma score less equal 2 child ) , convulsion ( witness ) , prostration , severe anemia ( hemoglobin le 5 g/dL ) , respiratory distress , hypoglycemia ( serum glucose less 40 mg/dL ) , jaundice/icetrus , renal insufficiency ( anuria 24 hour ) , hemoglobinuria , state shock ( systolic blood pressure le 50 mmHg , rapid pulse , cool extremity ) , cessation eat drinking , repetitive vomiting . EXCLUSION CRITERIA : Individuals live malaria endemic area asymptomatic anonmalaria illness sometimes incidentally noted parasitemic , patient parasitemic yet find clinical examination another etiology febrile illness ( e.g . respiratory tract infection ) exclude protocol , treat Cambodian Ministry Health staff malaria coexist infection . Pregnant woman also exclude protocol treat study physician guinine ( first trimester ) artemisininmefloquine ( second third trimester ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 14, 2011</verification_date>
	<keyword>Plasmodium Falciparum</keyword>
	<keyword>Hemoglobin E</keyword>
	<keyword>Mefloquine</keyword>
	<keyword>Artemisinin</keyword>
	<keyword>Piperaquine</keyword>
	<keyword>Malaria</keyword>
</DOC>